Owkin Licenses K Pro AI and MOSAIC Data to Servier for Oncology Research

Owkin announced an agreement on September 11, 2026, to license its AI scientist, K Pro, and multimodal patient data to Servier to advance oncology research. [1] Through this deal, Servier’s research teams will gain access to patient data from Owkin's MOSAIC network for analysis within the K Pro platform. [1] This licensing agreement represents the next phase of collaboration between the two companies, who previously worked together on patient subgroup identification in oncology. [1]

Owkin describes itself as an agentic AI company and states that K Pro combines patient data with specialized biological AI agents to support pharmaceutical decision-making. [1] The platform is designed to assist with molecule optimization, target discovery, biomarker identification, subgroup optimization, and clinical trial design. [1] K Pro has been trained and validated using real-world patient data alongside Owkin’s wet laboratory. [1] According to Servier’s executive vice president of research and development, Claude Bertrand, this combined access to patient data and AI-driven analysis allows researchers to generate and test hypotheses more quickly. [1]

The expanded partnership between Owkin and Servier highlights a growing industry reliance on agentic AI platforms to streamline complex pharmaceutical workflows. By transitioning from a targeted project on patient subgroup identification to a broader licensing of K Pro and the MOSAIC network, Servier is integrating Owkin's AI capabilities more deeply into its core oncology research. This move positions Owkin's combination of biological AI agents and real-world wet lab validation as a critical tool for target discovery and clinical trial design, shifting from bespoke consulting toward platform-as-a-service access. What the sources don't address: the specific financial terms of the licensing agreement and the exact duration of the expanded partnership.